{"id":"W4290851731","doi":"10.1016/j.jtct.2022.08.010","title":"The Cost-Effectiveness of Axicabtagene Ciloleucel as Second-Line Therapy in Patients with Large B-Cell Lymphoma in the United States: An Economic Evaluation of the ZUMA-7 Trial","year":2022,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Institutes of Health; Miltenyi Biotec; Kite Pharma; Division of Cancer Prevention, National Cancer Institute; Gilead Sciences; AstraZeneca; Bristol-Myers Squibb; National Cancer Institute; AbbVie; Merck; Roche; Astellas Pharma US; Amgen","keywords":"Medicine; Chemoimmunotherapy; Cost effectiveness; Quality-adjusted life year; Clinical trial; Oncology; Internal medicine; Lymphoma; Rituximab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00413934,0.0001569622,0.0002541187,0.0001665155,0.0001788785,0.00001915042,0.0002439408,0.00004923771,0.000525059],"category_scores_gemma":[0.000004467726,0.0000850576,0.00007213086,0.0004041223,0.0001141948,0.00006181554,0.000009251326,0.0002014814,6.631718e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001390891,"about_ca_system_score_gemma":0.0002595455,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003387228,"about_ca_topic_score_gemma":0.0002086162,"domain_scores_codex":[0.9958513,0.002616728,0.0003787749,0.0002288528,0.0007161851,0.0002080939],"domain_scores_gemma":[0.9989165,0.0003947678,0.0001637381,0.0003712797,0.0001180223,0.00003571051],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.689983,0.01071733,0.05409516,0.0002796398,0.0004195316,0.00001968227,0.03606736,0.006458394,0.09743915,0.0004905802,0.000009959316,0.1040202],"study_design_scores_gemma":[0.5285041,0.01135789,0.2711124,0.00008337739,0.0001148778,0.00001156524,0.004710353,0.007517975,0.1738357,0.0004442716,0.002014782,0.0002926162],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9946718,0.0004372185,0.00002766094,0.00009294539,0.00007764858,0.00439387,0.0001052737,0.000006138076,0.0001874003],"genre_scores_gemma":[0.9971178,0.001556183,0.000002136198,0.0001755667,0.0000165755,0.0003967781,0.0006512914,0.00002461745,0.00005906182],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2170173,"threshold_uncertainty_score":0.5749028,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0411253268733812,"score_gpt":0.3165985277671497,"score_spread":0.2754732008937685,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}